Angiogenesis as a therapeutic target in breast cancer

Mini Rev Med Chem. 2012 Oct;12(12):1230-8. doi: 10.2174/138955712802761988.

Abstract

Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several malignancies, including breast cancer. Bevacizumab is a monoclonal antibody that targets the vascular endothelial growth factor (VEGF). Recent clinical data have demonstrated that the addition of bevacizumab to first-line chemotherapy improves the progression-free survival of patients with advanced breast cancer. This review presents an update on the role of bevacizumab, as well as other anti-angiogenic agents in the management of patients with breast carcinoma.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacokinetics
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / pharmacokinetics
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab
  • Breast Neoplasms / blood supply
  • Breast Neoplasms / drug therapy*
  • Clinical Trials as Topic
  • Female
  • Half-Life
  • Humans
  • Neovascularization, Pathologic*
  • Protein Kinase Inhibitors / pharmacokinetics
  • Protein Kinase Inhibitors / therapeutic use
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Protein Kinase Inhibitors
  • Vascular Endothelial Growth Factor A
  • Bevacizumab